The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial

David Holmes, Peter Fitzgerald, Sheldon Goldberg, J. M. LaBlanche, A. Michael Lincoff, Michael Savage, P. W. Serruys, James Willerson, Jeffrey R. Granett, Robert Chan, Neil H. Shusterman, Marcia Poland

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Tranilast is a unique drug in clinical development for the prevention of restenosis after percutaneous transluminal coronary revascularization (PTCR). Tranilast interferes with proliferation and migration of vascular medial smooth muscle cells induced by platelet-derived growth factor and transforming growth factor β1. Collagen synthesis in vascular medial smooth muscle cells is inhibited by tranilast, which also inhibits the release or production of cyclooxygenase-2 and restores cytokine- induced nitric oxide production. These mechanisms may contribute to the reduction of angiographic restenosis after coronary intervention previously reported in clinical studies. Methods: The primary objective of this multicenter study of 11,500 patients is to compare the composite clinical event rate of death, myocardial infarction, or the need for ischemia-driven target vessel revascularization of tranilast (300 and 450 mg twice daily) for 1 or 3 months with that of placebo in patients undergoing PTCR with or without stenting for single or multiple vessels over a 9-month period. The lesions can be de novo or restenotic. All revascularization procedures and the use of glycoprotein IIb/IIIa agents are permitted. The inclusion criteria are meant to allow an 'all comer' approach for generalization of results to the broadest possible PTCR population. A subset population (n = 2000) will undergo 9-month follow-up angiography, 1000 of which will also undergo intravascular ultrasound (n- 1000). This study is the first tranilast trial to be conducted in a Western population to confirm the improved angiographic findings reported in Japanese patients and to determine if the clinical sequelae of restenosis are also reduced Conclusion: This multicenter study is the largest restenosis trial planned to date. If will test whether tranilast, a drug with multiple actions aimed at affecting proliferation and migration of vascular smooth muscle cells, can reduce clinical, angiographic, and intravascular ultrasound assessments of restenosis.

Original languageEnglish (US)
Pages (from-to)23-31
Number of pages9
JournalAmerican Heart Journal
Volume139
Issue number1 I
DOIs
StatePublished - Jan 1 2000

Fingerprint

Placebos
Percutaneous Coronary Intervention
Vascular Smooth Muscle
Smooth Muscle Myocytes
Multicenter Studies
Coronary Restenosis
Population
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet-Derived Growth Factor
Transforming Growth Factors
Cyclooxygenase 2
Pharmaceutical Preparations
tranilast
Angiography
Nitric Oxide
Collagen
Ischemia
Myocardial Infarction
Cytokines
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol : A double-blind, placebo-controlled trial. / Holmes, David; Fitzgerald, Peter; Goldberg, Sheldon; LaBlanche, J. M.; Lincoff, A. Michael; Savage, Michael; Serruys, P. W.; Willerson, James; Granett, Jeffrey R.; Chan, Robert; Shusterman, Neil H.; Poland, Marcia.

In: American Heart Journal, Vol. 139, No. 1 I, 01.01.2000, p. 23-31.

Research output: Contribution to journalArticle

Holmes, D, Fitzgerald, P, Goldberg, S, LaBlanche, JM, Lincoff, AM, Savage, M, Serruys, PW, Willerson, J, Granett, JR, Chan, R, Shusterman, NH & Poland, M 2000, 'The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial', American Heart Journal, vol. 139, no. 1 I, pp. 23-31. https://doi.org/10.1016/S0002-8703(00)90304-1
Holmes, David ; Fitzgerald, Peter ; Goldberg, Sheldon ; LaBlanche, J. M. ; Lincoff, A. Michael ; Savage, Michael ; Serruys, P. W. ; Willerson, James ; Granett, Jeffrey R. ; Chan, Robert ; Shusterman, Neil H. ; Poland, Marcia. / The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol : A double-blind, placebo-controlled trial. In: American Heart Journal. 2000 ; Vol. 139, No. 1 I. pp. 23-31.
@article{1f92e94e22a940f89e55921898316235,
title = "The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial",
abstract = "Background: Tranilast is a unique drug in clinical development for the prevention of restenosis after percutaneous transluminal coronary revascularization (PTCR). Tranilast interferes with proliferation and migration of vascular medial smooth muscle cells induced by platelet-derived growth factor and transforming growth factor β1. Collagen synthesis in vascular medial smooth muscle cells is inhibited by tranilast, which also inhibits the release or production of cyclooxygenase-2 and restores cytokine- induced nitric oxide production. These mechanisms may contribute to the reduction of angiographic restenosis after coronary intervention previously reported in clinical studies. Methods: The primary objective of this multicenter study of 11,500 patients is to compare the composite clinical event rate of death, myocardial infarction, or the need for ischemia-driven target vessel revascularization of tranilast (300 and 450 mg twice daily) for 1 or 3 months with that of placebo in patients undergoing PTCR with or without stenting for single or multiple vessels over a 9-month period. The lesions can be de novo or restenotic. All revascularization procedures and the use of glycoprotein IIb/IIIa agents are permitted. The inclusion criteria are meant to allow an 'all comer' approach for generalization of results to the broadest possible PTCR population. A subset population (n = 2000) will undergo 9-month follow-up angiography, 1000 of which will also undergo intravascular ultrasound (n- 1000). This study is the first tranilast trial to be conducted in a Western population to confirm the improved angiographic findings reported in Japanese patients and to determine if the clinical sequelae of restenosis are also reduced Conclusion: This multicenter study is the largest restenosis trial planned to date. If will test whether tranilast, a drug with multiple actions aimed at affecting proliferation and migration of vascular smooth muscle cells, can reduce clinical, angiographic, and intravascular ultrasound assessments of restenosis.",
author = "David Holmes and Peter Fitzgerald and Sheldon Goldberg and LaBlanche, {J. M.} and Lincoff, {A. Michael} and Michael Savage and Serruys, {P. W.} and James Willerson and Granett, {Jeffrey R.} and Robert Chan and Shusterman, {Neil H.} and Marcia Poland",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0002-8703(00)90304-1",
language = "English (US)",
volume = "139",
pages = "23--31",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1 I",

}

TY - JOUR

T1 - The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol

T2 - A double-blind, placebo-controlled trial

AU - Holmes, David

AU - Fitzgerald, Peter

AU - Goldberg, Sheldon

AU - LaBlanche, J. M.

AU - Lincoff, A. Michael

AU - Savage, Michael

AU - Serruys, P. W.

AU - Willerson, James

AU - Granett, Jeffrey R.

AU - Chan, Robert

AU - Shusterman, Neil H.

AU - Poland, Marcia

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: Tranilast is a unique drug in clinical development for the prevention of restenosis after percutaneous transluminal coronary revascularization (PTCR). Tranilast interferes with proliferation and migration of vascular medial smooth muscle cells induced by platelet-derived growth factor and transforming growth factor β1. Collagen synthesis in vascular medial smooth muscle cells is inhibited by tranilast, which also inhibits the release or production of cyclooxygenase-2 and restores cytokine- induced nitric oxide production. These mechanisms may contribute to the reduction of angiographic restenosis after coronary intervention previously reported in clinical studies. Methods: The primary objective of this multicenter study of 11,500 patients is to compare the composite clinical event rate of death, myocardial infarction, or the need for ischemia-driven target vessel revascularization of tranilast (300 and 450 mg twice daily) for 1 or 3 months with that of placebo in patients undergoing PTCR with or without stenting for single or multiple vessels over a 9-month period. The lesions can be de novo or restenotic. All revascularization procedures and the use of glycoprotein IIb/IIIa agents are permitted. The inclusion criteria are meant to allow an 'all comer' approach for generalization of results to the broadest possible PTCR population. A subset population (n = 2000) will undergo 9-month follow-up angiography, 1000 of which will also undergo intravascular ultrasound (n- 1000). This study is the first tranilast trial to be conducted in a Western population to confirm the improved angiographic findings reported in Japanese patients and to determine if the clinical sequelae of restenosis are also reduced Conclusion: This multicenter study is the largest restenosis trial planned to date. If will test whether tranilast, a drug with multiple actions aimed at affecting proliferation and migration of vascular smooth muscle cells, can reduce clinical, angiographic, and intravascular ultrasound assessments of restenosis.

AB - Background: Tranilast is a unique drug in clinical development for the prevention of restenosis after percutaneous transluminal coronary revascularization (PTCR). Tranilast interferes with proliferation and migration of vascular medial smooth muscle cells induced by platelet-derived growth factor and transforming growth factor β1. Collagen synthesis in vascular medial smooth muscle cells is inhibited by tranilast, which also inhibits the release or production of cyclooxygenase-2 and restores cytokine- induced nitric oxide production. These mechanisms may contribute to the reduction of angiographic restenosis after coronary intervention previously reported in clinical studies. Methods: The primary objective of this multicenter study of 11,500 patients is to compare the composite clinical event rate of death, myocardial infarction, or the need for ischemia-driven target vessel revascularization of tranilast (300 and 450 mg twice daily) for 1 or 3 months with that of placebo in patients undergoing PTCR with or without stenting for single or multiple vessels over a 9-month period. The lesions can be de novo or restenotic. All revascularization procedures and the use of glycoprotein IIb/IIIa agents are permitted. The inclusion criteria are meant to allow an 'all comer' approach for generalization of results to the broadest possible PTCR population. A subset population (n = 2000) will undergo 9-month follow-up angiography, 1000 of which will also undergo intravascular ultrasound (n- 1000). This study is the first tranilast trial to be conducted in a Western population to confirm the improved angiographic findings reported in Japanese patients and to determine if the clinical sequelae of restenosis are also reduced Conclusion: This multicenter study is the largest restenosis trial planned to date. If will test whether tranilast, a drug with multiple actions aimed at affecting proliferation and migration of vascular smooth muscle cells, can reduce clinical, angiographic, and intravascular ultrasound assessments of restenosis.

UR - http://www.scopus.com/inward/record.url?scp=0033973506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033973506&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(00)90304-1

DO - 10.1016/S0002-8703(00)90304-1

M3 - Article

C2 - 10618558

AN - SCOPUS:0033973506

VL - 139

SP - 23

EP - 31

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1 I

ER -